High-Purity EPA Agent for Suppressing Body Weight Gain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity agents are ineffective in suppressing body weight gain, particularly in cases with mild hepatic lipogenesis or fatty liver, and often have side effects or require dietary restrictions.
Innovation Solution
An agent comprising high purity ethyl icosapentaenoic acid (EPA-E) is developed, which effectively suppresses body weight gain and reduces low-density lipoprotein cholesterol (LDL-C) and cholesteryl ester transfer protein (CETP) activity, specifically designed for use in hamsters and potentially humans, without the need for low-calorie or low-fat diets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-obesity agents are used, then body weight gain suppression is attempted, but they are ineffective particularly in cases with mild hepatic lipogenesis or fatty liver
Solution Approach 1:
The patent uses high-purity EPA (90% or more by weight) at a specific dosage range (0.06-0.24 g/kg body weight per day) to achieve effective suppression of body weight gain. This parameter optimization resolves the contradiction by providing reliable effectiveness across different obesity types, particularly in cases with mild hepatic lipogenesis or fatty liver where conventional agents fail.
2Reliability
If dietary restrictions are imposed to suppress body weight gain, then weight reduction is achieved, but it requires low-calorie or low-fat diets which reduce quality of life
Solution Approach 1:
The patent extracts the essential anti-obesity function from complex dietary restrictions and concentrates it into a single active ingredient (high-purity EPA). This allows body weight suppression to be achieved through medication rather than restrictive diets, maintaining quality of life while achieving the desired weight control effect.
3Reliability
If high purity EPA is used to suppress body weight gain, then effectiveness is improved, but purity requirements increase manufacturing complexity
Solution Approach 1:
The patent specifies a purity threshold of 90% or more by weight for EPA, which balances manufacturing feasibility with therapeutic effectiveness. This parameter setting resolves the contradiction by establishing a clear, achievable purity standard that ensures reliability without requiring excessive manufacturing complexity.
Data Source
AI summary
The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.